Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$215.53 - $274.5 $1.8 Million - $2.29 Million
-8,358 Closed
0 $0
Q4 2022

May 15, 2023

BUY
$125.51 - $229.3 $1.05 Million - $1.92 Million
8,358 New
8,358 $1.84 Billion

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $14.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track La Banque Postale Asset Management Sa Portfolio

Follow La Banque Postale Asset Management Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of La Banque Postale Asset Management Sa, based on Form 13F filings with the SEC.

News

Stay updated on La Banque Postale Asset Management Sa with notifications on news.